Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Hamburg
Clinical trial register · Germany

Clinical Trials in Hamburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Berlin 118 Essen 60 Hamburg 55 Dresden 53 Cologne 49

Trials with a site in Hamburg

55 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
AstraZeneca
Phase 3
750
Berlin, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Oldenburg
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-19
Recruiting
AstraZeneca
Phase 3
600
Ahrensburg, Berlin, Bochum, Gladbeck, Hamburg, Hanover, Karlsruhe, Leipzig
2026-08-12
Recruiting
AstraZeneca
Phase 3
915
Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Hamburg, Hanover, Herne
2026-07-16
Recruiting
AstraZeneca
Phase 3
900
Bad Oeynhausen, Berlin, Brandenburg an der Havel, Chemnitz, Duisburg, Erlangen, Frankfurt, Hamburg
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Bad Oeynhausen, Bochum, Cologne, Dresden, Falkensee, Gera, Hamburg, Leipzig
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig
2026-06-26
Active, closed
AstraZeneca
Phase 2
326
Berlin, Cologne, Essen, Hamburg, Heidelberg, Homburg, München, Münster
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bonn, Coswig, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover
2026-06-11
Recruiting
AstraZeneca
Phase 3
245
Bad Abbach, Hamburg, Mainz, München
2026-04-13
Recruiting
AstraZeneca
Phase 3
508
Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz
2026-02-23
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1/2
27
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
2026-01-09
Recruiting
AstraZeneca
Phase 3
1,100
Berlin, Bonn, Detmold, Dresden, Düsseldorf, Essen, Frankfurt am Main, Hamburg
2025-12-29
Recruiting
AstraZeneca
Phase 2
320
Bad Doberan, Berlin, Hamburg, Sendenhorst
2025-12-15
Recruiting
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
AstraZeneca
Phase 3
1,100
Aachen, Berlin, Bonn, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg
2025-12-04
Recruiting
AstraZeneca
Phase 3
800
Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-08-01
Active, closed
AstraZeneca
Observational
2,000
Hamburg
2025-04-17
Active, closed
AstraZeneca
Phase 2
82
Berlin, Dresden, Essen, Hamburg, Marburg
2025-03-12
Recruiting
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
NCT06726720Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca
Observational
300
Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel
2024-12-16
Active, closed
AstraZeneca
Phase 3
768
Berlin-Zehlendorf, Essen, Georgsmarienhütte, Großhansdorf, Hamburg, Löwenstein, Nuremberg
2024-10-04
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
AstraZeneca
Phase 2
257
Cologne, Frankfurt, Gauting, Großhansdorf, Hamburg, Heidelberg, Mainz, Münster
2024-08-22
Recruiting
AstraZeneca
Phase 3
620
Berlin, Bonn, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Berlin, Deggendorf, Düsseldorf, Göttingen, Hamburg, Heidelberg, Jena, Karlsruhe
2024-08-07
Active, closed
AstraZeneca
Phase 3
594
Berlin, Frankfurt, Göttingen, Hamburg, Heidelberg, Heilbronn, Leipzig, Marburg
2024-03-04
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Berlin, Cologne, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hamburg
2023-12-29
Recruiting
AstraZeneca
Phase 3
1,145
Berlin, Erlangen, Essen, Freiburg im Breisgau, Greifswald, Hamburg, Hanover, Leipzig
2023-12-14
Recruiting
AstraZeneca
Phase 1/2
226
Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg
2023-12-05
Active, closed
AstraZeneca
Phase 3
760
Berlin, Bonn, Dortmund, Dresden, Erlangen, Esslingen A. N., Frankfurt, Hamburg
2023-12-04
Active, closed
AstraZeneca
Phase 3
863
Berlin, Bochum, Cologne, Essen, Gauting, Georgsmarienhütte, Großhansdorf, Hamburg
2023-11-09
Recruiting
AstraZeneca
Phase 3
800
Berlin, Bonn, Hamburg, Leipzig
2023-09-22
Active, closed
AstraZeneca
Phase 3
1,350
Bad Berka, Berlin, Frankfurt A. Main, Gauting, Gütersloh, Hamburg, Kassel, Kiel
2022-12-29
Recruiting
AstraZeneca
Phase 3
3,527
Augsburg, Berlin, Cologne, Hamburg, Hanover, Kiel, Leverkusen, Marburg
2022-12-13
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Dresden, Duisburg, Hamburg, Hanover, München, Tübingen
2022-05-23
Active, closed
AstraZeneca
Phase 3
760
Bonn, Chemnitz, Dresden, Düsseldorf, Frankfurt, Göttingen, Hamburg, Hanover
2022-03-28
Active, closed
AstraZeneca
Phase 1/2
36
Hamburg, München, Tübingen
2022-01-21
Active, closed
AstraZeneca
Phase 3
145
Hamburg, Tübingen, Würzburg
2021-11-19
Active, closed
AstraZeneca
Phase 3
148
Hamburg, Hanover, München, Ulm
2021-10-28
Active, closed
AstraZeneca
Phase 3
927
Augsburg, Berlin, Erlangen, Hamburg, Heidelberg, Kiel, Leipzig, Mönchengladbach
2021-10-25
Active, closed
AstraZeneca
Phase 3
506
Berlin, Dresden, Erlangen, Essen, Frankfurt, Hamburg, Hanover, Kiel
2021-06-22
Active, closed
AstraZeneca
Phase 3
1,157
Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2021-04-26
Active, closed
AstraZeneca
Phase 3
957
Berlin, Dresden, Frankfurt, Hamburg, Heidelberg, Heilbronn, Jena, Mainz Am Rhein
2020-11-17
Active, closed
AstraZeneca
Phase 3
1,012
Berlin, Duisburg, Hamburg, Herne, Mettmann, Münster, Nuremberg, Nürtingen
2020-07-13
Active, closed
AstraZeneca
Phase 2
452
Frankfurt, Hamburg, Leipzig, Mannheim, München
2020-06-03
Active, closed
AstraZeneca
Phase 3
818
Dresden, Erlangen, Essen, Frankfurt, Gelsenkirchen, Hamburg, Hanover, Heidelberg
2020-04-16
Active, closed
AstraZeneca
Phase 3
140
Bamberg, Freiburg im Breisgau, Hamburg, Kirchheim, Lübeck
2019-10-29
Active, closed
AstraZeneca
Phase 2
273
Dresden, Frankfurt am Main, Hamburg, Hanover, Leipzig, München, Witten
2018-03-07
Active, closed
AstraZeneca
Phase 3
1,186
Berlin, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Immenhausen, Mainz
2017-06-01
Active, closed
AstraZeneca
Phase 3
987
Aachen, Berlin, Gauting, Gera, Hamburg, Heidelberg, Mainz, Regensburg
2017-03-27
Active, closed
AstraZeneca
Phase 3
1,118
Aachen, Bad Berka, Berlin, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Hemer
2015-07-21
Rows per page Showing 1–55 of 55
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 November 2026. https://priyalifescience.com/clinical-trials-germany/city/hamburg

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 55 of those studies with a site in Hamburg that also match the filters currently applied.

How many clinical trials are recruiting in Hamburg?

28 of the 55 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hamburg), 55 studies
PhaseStudiesRecruitingShare
Phase 3392070.9%
Phase 29416.4%
Phase 1/2437.3%
Observational315.5%

Most active sponsors

Lead sponsors with the most studies (Hamburg)
Lead sponsorStudiesRecruiting
AstraZeneca5528
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.